Eidos Therapeutics raises $106M IPO to advance ATTR med

Rare disease biotech Eidos Therapeutics priced its IPO at $17 a share, hauling in about $106.3 million to push its treatment for transthyretin (TTR) amyloidosis through the clinic. The offering comes on the heels of a $64 million series B round, completed in April.